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IMPORTANCE Lung cancer is the leading cause of cancer death in the United States in all
ethnic and racial groups. The overall death rate from lung cancer is higher in black patients
than in white patients.
OBJECTIVE To compare the prevalence and types of somatic alterations between lung
cancers from black patients and white patients. Differences in mutational frequencies could
illuminate differences in prognosis and lead to the reduction of outcome disparities bymore
precisely targeting patients’ treatment.
DESIGN, SETTING, AND PARTICIPANTS Tumor specimenswere collected fromBaptist Cancer
Center (Memphis, Tennessee) over the course of 9 years (January 2004-December 2012).
Genomic analysis by massively parallel sequencing of 504 cancer genes was performed at
Dana-Farber Cancer Institute (Boston, Massachusetts). Overall, 509 lung cancer tumors
specimens (319 adenocarcinomas; 142 squamous cell carcinomas) were profiled from 245
black patients and 264white patients.
MAIN OUTCOMES ANDMEASURES The frequencies of genomic alterations were compared
between tumors from black and white populations.
RESULTS Overall, 509 lung cancers were collected and analyzed (273 women [129 black
patients; 144 white patients] and 236men [116 black patients; 120 white patients]). Using 313
adenocarcinomas and 138 squamous cell carcinomas with genetically supported ancestry,
overall mutational frequencies and copy number changes were not significantly different
between black and white populations in either tumor type after correcting for multiple
hypothesis testing. Furthermore, specific activating alterations in members of the receptor
tyrosine kinase/Ras/Raf pathway including EGFR and KRASwere not significantly different
between populations in lung adenocarcinoma.
CONCLUSIONS AND RELEVANCE These results demonstrate that lung cancers from black
patients are similar to cancers fromwhite patients with respect to clinically actionable
genomic alterations and suggest that clinical trials of targeted therapies could significantly
benefit patients in both groups.
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L ungcancer remains the leadingcauseofdeath fromcan-cer in the United States.1 Black populations have thehighest lung cancer mortality rate of any racial or eth-
nic group in the United States.2 The average annual age-
adjusted incidence is 65.0 and 58.8 per 100000 in black pa-
tients and white patients, respectively.2 Many factors may
contribute to thedisparities inboth incidenceandoutcome in-
cluding differences in access to health care, smoking behav-
ior, and other socioeconomic variables.3-5 However, these
known risk factors do not fully explain the differences in the
incidence and outcome between these 2 populations.6-8
Acquired alterations to the cancer genome—including so-
matic single-nucleotide variants, insertions anddeletions (in-
dels), copy number variations (CNVs), and structural rear-
rangements—contribute to tumorigenesis by activating
pathways involved in cell growth and proliferation, resis-
tance to apoptosis, and immune cell invasion.9 Alterations in
receptor tyrosinekinases (RTKs) suchasEGFR,ALK,RET, and
ROS1 are clinically important as they confer sensitivity to ki-
nase inhibitors in lungadenocarcinomas.10,11Recentstudies12-14
led by our group and The Cancer Genome Atlas (TCGA) have
performedcomprehensivemolecular characterizationof lung
tumors to identify other potentially targetable alterations.We
have shown that the frequencyof acquired alterations in lung
cancer driver genes are largely distinct between the 2 largest
subclasses of non–small-cell lung cancer (NSCLC), lung ad-
enocarcinoma, and lung squamous cell carcinoma.15
Inadditiontohistology,thefrequencyofacquiredalterations
in lung tumors can vary across sex, smoking status, and ances-
tralpopulations.10Forexample,EGFRkinasedomainmutations
occur at a significantly higher frequency in lung adenocarcino-
masfromwomencomparedwithmen,never-smokerscompared
with smokers, andEastAsianpopulations comparedwithnon-
Asianpopulations.10,16,17Thehigher ratesofEGFRmutations in
these populations have resulted in a corresponding higher rate
of patientswith clinical response toEGFR inhibitors.18-20 Stud-
iesexaminingmutationalprofilesofEGFR intumorsfrompatients
withblackancestryhavebeenlessconclusive.Somestudieshave
reported significantly lower frequencies of EGFRmutations in
blackpatientscomparedwithwhites,21-24whileotherstudiesdid
notobserveanyassociationofEGFRmutationstatuswithances-
tryorself-reportedrace.25-28Theinterpretationof thesefindings
have been limited by the presence of confounding factors such
assexandsmokingstatusorbythefact thatcohortswerepooled
together fromdifferent clinical settingsacrossdifferent institu-
tions.MovingbeyondEGFR, amore recent study25examininga
panelofknowndrivermutationsacrossseveralhundredNSCLC
samplesfoundaloweroverall frequencyofmutationsinanygene
in tumors fromblack patients comparedwithwhite patients.25
However,nostudieshavebeenperformedthatcomprehensively
characterizegenomicalterationsacrosshundredsofwell-known
cancer genes in a large number of tumors from both black and
white populations.
To understand the relationship between tumoral genomic
alterations and black ancestry, we profiled the exome se-
quencesof504cancergenes in509 lungcancers fromblackpa-
tientsandwhitepatients.These tumorswerecollected frompa-
tients in the same clinical setting and were well matched for
clinical covariates. We did not identify enrichment of muta-
tions or copy number changes in either population. These re-
sultssuggest that targetedtherapiesandbiomarker-drivenclini-
cal trials should significantly benefit patients in both groups.
Methods
Sample Collection
Formalin-fixed paraffin-embedded (FFPE) lung tumor speci-
mens were collected from black and white patients from Bap-
tist Cancer Center inMemphis, Tennessee. All specimenswere
obtained frompatientswithapproval fromthe relevant institu-
tional review boards. Lung cancer cases from January 2004 to
December 2012were identified from a search of pathology de-
partment records across 3 health care systems (Baptist Memo-
rialHealthCare,Methodist-LeBonheurHealthcare,andStFran-
cisHealthcare) inmetropolitanMemphis.Racewascategorized
by patient self-identification. From each institution, speci-
mensfromblackpatientswerepairedwithspecimensfromwhite
patients bymatching for histology, sex, and age.
Sequencing and Analysis
In total, 607 tumors underwent DNA isolation and sequenc-
ingof504cancer-relatedgenesusing theOncoPanelplatform29
(eMethods in Supplement 1 and eTable 1 in Supplement 2).
Overall, 550 librarieswith sufficientmaterial were submitted
for sequencing. Thirty tumors were excluded for failing se-
quencing quality control (eMethods in Supplement 1), and an
additional 11 tumors were excluded due to insufficient clini-
cal annotation, leaving a total of 509 tumors for analysis. Data
werealignedandprocessedaspreviouslydescribed (eMethods
inSupplement 1).30-33 Principal component analysis (PCA)34,35
and other statistical analyses are described in eMethods in
Supplement 1. Because we did not have paired normal tissue
for these patients, we excluded variants found in exomes of
noncancer tissueusing theExomeAggregationConsortiumda-
tabase (eFigure 1 in Supplement 1).
Results
Study Cohort
In total, 509 tumor specimens from245blackpatients and264
white patientswere analyzed (Table) (eTable 2 in Supplement
Key Points
Question Are themutational profiles of lung cancers different
between black and white patients?
Findings In this genomic analysis of a cohort of patients with lung
cancer, mutational frequencies were not significantly different
between black and white populations in both lung
adenocarcinoma and lung squamous cell carcinoma.
Meaning Differences in mutational profiles do not likely
contribute to the increased incidence andmortality of lung cancer
in black populations.
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2).This included319adenocarcinomas, 142 squamouscell car-
cinomas, 47 NSCLC of other histology, and 1 small-cell carci-
noma. Twenty-nine samples were obtained from a biopsy of
a nonlung site for a putative lung cancer metastasis. Thema-
jority of tumors were stage I (n = 305) or stage II (n = 98). We
performed secondary pathological review for 380 lung can-
cers (eMethods in Supplement 1) and confirmed histological
classification in 223 of 247 lung adenocarcinomas (90%) and
80 of 97 squamous cell carcinomas (82%).
Association of Self-reported RaceWith Germline Variation
Previous studies have noted that self-reported clinical vari-
ables such as race and sex are not always congruent with un-
derlyingbiological ancestry or sex asdefinedbygenetic varia-
tionandstructure.36Toexamine the relationshipbetweenself-
reported race and biological ancestry, we performed PCA on
single-nucleotidevariants (SNVs) likely tobe inheritedandnot
somatically acquired (eMethods and eFigure 1 in Supplement
1). Principal component 1 (PC1) was strongly associated with
self-reported race (Wilcoxon rank-sum test P = 7.6 × 10−79)
(Figure 1). TwoSNVprofiles fromreportedwhitepatients clus-
tered with the samples from black patients, and 6 SNV pro-
files fromreportedblackpatients clusteredwith thewhite pa-
tient samples.Additionally, 3 sampleswereoutliers alongPC2.
These 11 samples were excluded from all further analyses ex-
amining the association between ancestry and genomic al-
terations.
Mutational Signatures
Various exogenous exposures or endogenous biological pro-
cesses can contribute to the overallmutational load observed
in lung tumors. We identified 4 mutational signatures pres-
ent in the cohort37 (eMethods in Supplement 1). These signa-
tures were strongly correlated with previously characterized
signatures of smoking (designated as SI4), aberrant APOBEC
(apolipoprotein B messenger RNA editing enzyme, catalytic
polypeptide-like) activity (SI2 and SI13), mismatch repair
(MMR) and aging (SI6/SI15 and SI1/SI5), and ultraviolet (UV)
radiation exposure (SI7) (Figure 2) (eFigure 2 in Supplement
1).38 The smoking-related signature SI4 was enriched for cy-
tosine (C)>adenine (A) transversions and strongly associated
with smoking status in lung adenocarcinoma (P = 9.1 × 10−15)
(Figure 2) and to a lesser extent in lung squamous cell carci-
noma (P = .08). No signatures were associatedwith ancestry,
suggesting that themutagenicprocesses are similar in lung tu-
mors from black and white populations in lung adenocarci-
Table. Cohort Demographics by Self-reported Racea
Characteristic Black (n = 245) White (n = 264) All P Value
Sex
Male 116 120 236
.72
Female 129 144 273
Pack-years
Median (range) 30 (0-120) 40 (0-120) 38 (0-120)
<.001
NA 35 35 70
Smoking status
Never 26 23 49
.33
Former
Heavy 92 116 208
Light 18 12 30
Active
Heavy 86 88 174
Light 19 14 33
NA 4 11 15
Histology
NSCLC
Adenocarcinoma 150 169 319
.94
Squamous 69 73 142
Large-cell undifferentiated 8 6 14
Adenosquamous 6 7 13
Large-cell neuroendocrine 5 5 10
Undefined 6 4 10
Small-cell carcinoma 1 0 1
Stage
I 142 163 305
.60
II 53 45 98
III 28 32 60
IV 10 9 19
NA 12 15 27
Abbreviations: NA, not applicable or
no data available; NSCLC,
non–small-cell lung cancer.
a Unless otherwise indicated, data are
reported as number of patients.
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noma or lung squamous cell carcinoma (P > .05 for all) (eFig-
ure 3 in Supplement 1).
Lack of Association Between Genomic Alterations
and Ancestry
Toassess the relationshipbetweenancestry andmutation sta-
tus, we examined the mutational frequencies in 313 lung ad-
enocarcinomas and 138 lung squamous cell carcinomas. This
set excluded 6 adenocarcinomas and 4 squamous cell carci-
nomas frompatientswhoseancestrywasnotconfirmedonPC1
orwere outliers on PC2 in the PCA analysis (Figure 1). Clinical
variables were not significantly associated with ancestry in
either set of tumors with the exception of smoking pack-
years (P < .05 for all) (eTables 3 and 4 in Supplement 2). The
total number of putative somatic mutations, the percentage
of genes amplified, or the percentage of genes deleted per
tumor were not associated with ancestry (eFigure 4 in
Supplement 1). Similarly, other quality control metrics were
not associated with ancestry (eFigure 4 in Supplement 1).
Whenexaminingpreviously characterizedcancer genes in
lung adenocarcinoma, the most commonly mutated onco-
genes includedKRAS (34%),EGFR (14%), andBRAF (7%),while
themostcommonlymutated tumorsuppressors includedTP53
(60%),STK11 (14%), andARID1A (9%) (Figure3).Themostcom-
monly mutated lung squamous cell carcinoma oncogenes in-
cludedNFE2L2 (12%), and PIK3CA (9%)while tumor suppres-
sors included TP53 (88%), CDKN2A (17%), and PTEN (14%)
(eFigure 5 in Supplement 1). Using theFisher exact test,wedid
notobserveanystatisticalassociationbetweenancestryandmu-
tation frequencies for anygeneafter correction formultiplehy-
pothesis testing in either tumor type (FDR Q > .05) (eTables 5
and 6 in Supplement 2).We also compared themutational fre-
quencies in this cohortwith themutational frequencies found
in tumors from TCGA and related studies.15 In lung adenocar-
cinoma,TP53hadahighermutation frequency in tumors from
blackpatients (P = .02),NF1hada lowermutation frequency in
tumorsfromwhitepatients (P = .045),andKEAP1hadlowermu-
tational frequencies in tumors frombothpopulations (P < .001)
in this cohort compared with tumors from TCGA (n = 660)
(Figure3).Nosignificantdifferenceswereobservedbetweenthe
lungsquamouscell carcinomas fromthiscohortandthose from
TCGA(n = 484)using theFisherexact test (P > .05 forall) (eFig-
ure 5 in Supplement 1).
We also determined if the number of copy number gains
or losses for individual genes was significantly different be-
tween populations in either tumor type. Similar to themuta-
tional profiles, we did not observe significant differences af-
ter correction formultiple hypothesis testing for themajority
of genes (eFigures 6 and 7 in Supplement 1; eTables 7-10 in
Supplement 2). The only exception is SULT1A1, which dis-
played amodestly significantly higher number of gains in tu-
mors fromblackpatients (FDRQ = .06).Finally,while thenum-
Figure 1. Association of Germline VariationWith Self-reported Race Using PCA
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We identified single-nucleotide variations (SNVs) that were likely to be germline
(ie, inherited and not acquired) due to their presence in African American or
non-Finnish European (NFE) populations at a frequency of at least 1%.We
performed principal component analysis (PCA) on these SNVs (n = 3517) and
found that principal component 1 (PC1) was strongly correlated with
self-reported race (P = 7.6 × 10−79). Two reported white patients strongly
clustered with the black population, and 6 reported black patients strongly
clustered with the white population. Themisclustering of these patients could
be due to errors in clinical data collection or differences in the patient’s
self-perceived race from their biological ancestry. The samples from these
patients were excluded from further analyses examining the relationship
between ancestry and genomic alterations.
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bers were too small for statistical evaluation in lung
adenocarcinoma,weobservedoneALK rearrangementandone
ROS1 rearrangement in tumors from black patients (Figure 3)
(eTable 11 inSupplement2).TwoRET rearrangementswereob-
served in tumors fromwhite patients.
Ras/Raf/RTK Pathway Alterations in Lung Adenocarcinomas
FromBlack Patients
In lung adenocarcinoma, alterations in members of the Ras/
Raf/RTK signaling pathways are of particular interest be-
cause they confer sensitivity to clinically approved targeted
therapeutics.39 We first examined the mutational profile of
EGFRandobserved46mutationsacross41 tumors (Figure4A).
Five tumors had more than one EGFR mutation including
p.V769M/p.ELREA746del, p.S768I/p.V769L, p.V769M/
p.L858R, p.T790M/p.L858R, and p.G719A/p.L861Q. In-frame
indels in exon 19were observed in bothmen andwomen and
didnot showenrichment inblackvswhitewomenashasbeen
previously reported23 (Fisher exact P = .80). The overall fre-
quencyof activatingEGFRmutationswasnot associatedwith
Figure 2. Mutational Signatures in Tumors FromBlack andWhite Populations
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A, Four mutational signatures were identified using nonnegative matrix
factorization on 96 trinucleotide mutation types across 509 lung tumors
including those related to smoke exposure (SI4), aberrant APOBEC activation
(SI13 and SI2), aging (and SI1/5) andmismatch repair (SI15/6), and UV exposure
(SI7). Each bar corresponds to the probability of observing a particular mutation
in a trinucleotide context within each signature. B, The smoking signature was
associated with smoking status in lung adenocarcinoma (P = 9.1 × 10−15) and to
a lesser extent lung squamous cell carcinomas (P = .08). MMR indicates
mismatch repair.
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ancestry (P = .51) (Figure 4B). Using lung adenocarcinomas
frompatientswith sufficient clinical annotation (n = 303),we
performed logistic regression examining EGFRmutation sta-
tus as a function of ancestry, sex, and smoking status. A sig-
nificant increase was observed in never-smokers compared
with ever-smokers (P = 2.85 × 10−6), and amodest increase in
females compared with males (P = .08). However, no signifi-
cant association was observed between EGFR mutation sta-
tusandancestry (P = .35) (eFigure8 inSupplement 1andeTable
12 in Supplement 2).
To determine if the overall frequency of mutations from
any gene in the pathway was associated with race, we desig-
nated lung adenocarcinomas that had apreviously character-
ized activating somatic single-nucleotide variants, indel, am-
plification,orgene fusion inaknownRTK/Ras/Rafdriver13,40,41
as “oncogenepositive” (n = 128)while the remaining lung ad-
enocarcinomaswereconsidered“oncogenenegative” (n = 185).
Only fusionswithcanonicalbreakpointswereconsidered.MET
andERBB2were considered amplified if the tumor had a log2
copy number ratio greater than 1.15 Ancestry was not signifi-
cantly associatedwithoncogenenegative statususingaFisher
exact test (P = .36) (Figure4B).This lackofassociationwasalso
observed in a logistic regression model controlling for smok-
ing status and sex (P = .36) (eFigure 8 in Supplement 1 and
eTable 13 inSupplement2).These results indicate that thepro-
portions of Ras/Raf/RTK pathway alterations are similar be-
Figure 3. Frequencies ofMutations and Fusions for Known Lung AdenocarcinomaDriver Genes
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The frequencies of putative acquired alterations in each gene were compared
between tumors from black and white ancestry using the Fisher exact test. No
lung cancer genes reached statistical significance after correction for multiple
hypothesis testing (FDRQ > .05). Frequencies of alterations are shown for
previously characterized oncogenes and tumor suppressors in lung
adenocarcinoma.13,15 These frequencies are also compared with those found in
a cohort of 660 lung adenocarcinomas (LUAD) from TCGA and related
studies.13,15 Footnotes indicate a significant difference between themutational
frequencies in tumors from black patients in this cohort from those from TCGA
using the Fisher exact test (aP < .05; bP < .01; cP < .001) or a significant
difference between tumors fromwhite patients in this cohort and those from
TCGA (dP < .05; eP < .01). Columns correspond to tumors and rows correspond
to genes or clinical annotation. The individual boxes are colored according to
the type of alteration for that gene in that tumor. NA indicates not applicable.
Research Original Investigation Lung Cancer Mutations Among Black andWhite Populations
E6 JAMAOncology Published online January 19, 2017 (Reprinted) jamaoncology.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/oncology/0/ on 05/03/2017
Copyright 2017 American Medical Association. All rights reserved.
tween lung cancer patients fromblack andwhite populations
in this study population.
Discussion
The primary goal of this study was to determine if the fre-
quencies of putative acquired alterations in lung tumors are
different between black and white ancestries. We examined
variants in 504 genes from 313 lung adenocarcinomas and
138 lung squamous cell carcinomas and did not observe
associations between ancestry and somatic genomic altera-
tions within each histological subtype. As the targeted
sequencing panel used in this study was limited to cancer
genes, we did not have the ability to perform comprehen-
sive ancestral inference and classification. However, we
were able to capture SNVs in the cancer genes likely to be
inherited due to their relatively high frequency in nondis-
ease tissue from the Exome Aggregation Consortium data-
base. We observed that the variation among these markers
was strongly associated with self-reported race and largely
confirmed the status of the self-reported race annotation in
the majority of cases. The misclustering of tumors from 8
patients could be owing to errors in clinical data collection
or differences in the patient’s self-identified race from their
biological ancestry.
We observed 4mutational signatures that have been pre-
viously characterized in cancer38 including those related to
smoke exposure, aberrant APOBEC activity,42 MMR defi-
ciency or aging, and UV exposure. Similar to 3 tumors from
TCGA,15 we observed a single lung squamous cell carcinoma
fromawhitemale patient that had a pattern of UV-associated
mutations often observed in skin cancers and may represent
a metastasis to the lung.
Several previous studies have compared mutational fre-
quencies between lung tumors fromblack andwhite patients
andhavereportedconflictingresults.Mostof theseearlier stud-
ies have focused on EGFR owing to its importance as a clini-
cally actionable target and its higher prevalence in East Asian
populations. Studies by Leidner et al24 and Yang et al21 re-
ported statistically significant lower frequencies ofEGFRmu-
tations inblackpatients comparedwithwhitepatients; Bauml
etal22 reported lower frequencies inblack femalesmokerscom-
pared with white female smokers; and Bollig-Fischer et al23
foundhigher ratesofEGFRexon19 indels inblack femalescom-
pared with white females. In contrast, Cote et al,28 Reiners-
man et al,27 Yamaguchi et al,26 and Araujo et al25 did not ob-
serve any association of EGFR mutations with race. Of the
studies that did not reach statistical significance, Reiners-
man et al27 found a higher frequency of EGFR mutations in
blacks,while theothers found lower frequencies.25,26,28Over-
all, the frequency of EGFRmutations in black patients across
all of these studies range from2%to 19%.25 Several confound-
ing factorsmay contribute to thesediscrepancies. First,EGFR
mutation frequency varies by both smoking history and by
sex.36 While some studies were balanced for clinical covari-
ates between populations or used logistic regression to con-
trol for unbalanced variables,22-25 other studies did not take
this into consideration.21,26,27Furthermore, somestudiesused
lung tumors from black patients that were collected in differ-
ent clinical settings21,24,25,27 or were profiled with a different
genomic technology25 than the tumors collected from white
patients. Comparisons of populations collected in different
clinical settings may be influenced by factors such as sample
quality, inclusion criteria, regional smoking behavior, and ac-
cessibility to health care, which are difficult to quantify and
control in statistical models.
Figure 4. KnownActivating Ras/Raf/RTK Pathway Alterations in Tumors
FromBlack andWhite Populations
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Total: 146 167
Mutated: 82 103
Total: 146 167
Mutated: 17 24
We examined previously characterized activating mutations in genes that are
members of the Ras/Raf/RTK pathway.13,15 A, A total of 23 activating
single-nucleotide variations (SNVs) and 23 in-frame indels were found in EGFR
across 313 lung adenocarcinomas. Thesemutations are grouped by smoking
status, sex, and ancestry. One EGFR p.L858Rmutation in tumor from awhite
female is not shown in this figure due to lack of smoking annotation. B, We did
not observe a significant enrichment or depletion of known activating
mutations in EGFR (left) or all activating mutations in the pathway (right)
between tumors from black and white populations (P > .05 for all).
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More recent studies have moved beyond EGFR and KRAS
to profilingmutations across panels of genes. Bollig-Fischer et
al23 examined214codingmutations in26cancergenesandob-
served thatEGFRexon19 indelswereenriched inblackwomen
(P = .048). Araujo et al25 examined 38 SNVs across 8 genes as
well as EGFR and ERBB2 indels and ALK translocations. They
didnot findanysignificantdifferences in individual genes, but
didobserveanoverall reductioninthefrequencyoftumorsfrom
blackpatients thathadanydriveralteration (P = .04).Duetothe
exploratory nature of these studies, no correction formultiple
hypothesis testingwasperformed.However, foregoing thiscor-
rection increases the risk of observing false positives due to
chanceand reduces the likelihoodof replication in future stud-
ies. This may be a contributing factor in our inability to repli-
cate the findings from these studies.
Our cohort of lung cancers was collected from institu-
tions in the same region and clinical setting, profiledwith the
same DNA sequencing assay and was well matched for clini-
cal variableswith the exception of pack-years of smoking. Al-
though the value of pack-years was associatedwith ancestry,
we did not observe significant differences in the smoking-
associated signature (SI4) suggesting that differences be-
tween the populations in smoke exposure areminimal in our
cohort. While this study profiled the largest number of genes
comparedwithanyof theprevious studies,wecannot ruleout
the possibility that another gene outside of our assayed re-
gions will have substantially different mutational frequen-
cies betweenblack andwhitepopulations.However, since the
previously characterized recurrently altered genes in both tu-
mor types12,13,15 didnot display significant differences,webe-
lieve that thepossibility of another genedisplaying strongdif-
ferences between populations is unlikely. We did observe a
modest increase in the proportion of tumors with copy num-
ber gains in SULT1A1 from black patients. However, the vari-
ability in this region is likelygermlineaspreviously reported.43
Limitations
The mutational frequencies in this cohort were not signifi-
cantlydifferent fromthoseobserved inTCGAcohorts formost
genes suggesting that the tumors in our cohort are not sub-
stantially different from those in TCGA. The only exceptions
were in lung adenocarcinoma and included the tumor sup-
pressors TP53, NF1, and KEAP1. Because we did not have ac-
cess topairednormal tissue,we limited themissenseandsplice
sitemutations in our analysis to those previously observed in
human cancers as annotated in theCOSMIC (CatalogueOf So-
maticMutations InCancer) database. Thismayhave led to the
exclusion of some true novel somatic mutations and contrib-
uted to the lower mutational frequencies observed in these
genes.
Conclusions
In addition to themutational frequencies of individual genes,
we examined the differences in the frequency of previously
curatedRas/Raf/RTKpathway alterations known to drive cel-
lular transformation in lungadenocarcinoma.Weagaindidnot
observe significant associationsbetweenancestryand themu-
tational frequencies of thepathwaymembers included in this
panel. Therefore,webelieve that clinical sequencing coupled
with targeted therapies against these alterations will benefit
patients inbothpopulations.Overall, these results suggest that
differences in exomic mutations do not contribute to the ob-
served racial disparities in incidence and mortality between
black andwhite populations. Further investigation into other
genomic factors such asmutations in noncoding regions, epi-
genetic alterations, and gene expression changes or other
socioeconomic variables beyond smoking behavior and
access to health care may be required to fully explain these
disparities.
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